<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33688642</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2693-5015</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2021</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Research square</Title><ISOAbbreviation>Res Sq</ISOAbbreviation></Journal><ArticleTitle>More Than 50 Long-Term Effects of COVID-19: A Systematic Review and Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">rs.3.rs-266574</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.21203/rs.3.rs-266574/v1</ELocationID><Abstract><AbstractText><b>Background.</b> COVID-19, caused by SARS-CoV-2, can involve sequelae and other medical complications that last weeks to months after initial recovery, which has come to be called Long-COVID or COVID long-haulers. This systematic review and meta-analysis aims to identify studies assessing long-term effects of COVID-19 and estimates the prevalence of each symptom, sign, or laboratory parameter of patients at a post-COVID-19 stage. <b>Methods</b> . LitCOVID (PubMed and Medline) and Embase were searched by two independent researchers. All articles with original data for detecting long-term COVID-19 published before 1 <sup>st</sup> of January 2021 and with a minimum of 100 patients were included. For effects reported in two or more studies, meta-analyses using a random-effects model were performed using the MetaXL software to estimate the pooled prevalence with 95% CI. Heterogeneity was assessed using <i>I</i> <sup>2</sup> statistics. This systematic review followed Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) guidelines, although the study protocol was not registered. <b>Results.</b> A total of 18,251 publications were identified, of which 15 met the inclusion criteria. The prevalence of 55 long-term effects was estimated, 21 meta-analyses were performed, and 47,910 patients were included. The follow-up time ranged from 14 to 110 days post-viral infection. The age of the study participants ranged between 17 and 87 years. It was estimated that 80% (95% CI 65-92) of the patients that were infected with SARS-CoV-2 developed one or more long-term symptoms. The five most common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%). All meta-analyses showed medium (n=2) to high heterogeneity (n=13). <b>Conclusions</b> . In order to have a better understanding, future studies need to stratify by sex, age, previous comorbidities, the severity of COVID-19 (ranging from asymptomatic to severe), and duration of each symptom. From the clinical perspective, multi-disciplinary teams are crucial to developing preventive measures, rehabilitation techniques, and clinical management strategies with whole-patient perspectives designed to address long COVID-19 care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lopez-Leon</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wegman-Ostrosky</LastName><ForeName>Talia</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Cancerolog&#xed;a: Instituto Nacional de Cancerologia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perelman</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Autonomous University of Mexico: Universidad Nacional Autonoma de Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepulveda</LastName><ForeName>Rosalinda</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Harvard University T H Chan School of Public Health.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rebolledo</LastName><ForeName>Paulina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Emory University School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuapio</LastName><ForeName>Angelica</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Karolinska Institute: Karolinska Institutet.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villapol</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6174-4113</Identifier><AffiliationInfo><Affiliation>Houston Methodist Research Institute.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 NS106640</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Res Sq</MedlineTA><NlmUniqueID>101768035</NlmUniqueID><ISSNLinking>2693-5015</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Sci Rep. 2021 Aug 9;11(1):16144. doi: 10.1038/s41598-021-95565-8</RefSource><PMID Version="1">34373540</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement><b>Competing interests.</b> The authors are solely responsible for all content, and funders played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare that they have no competing interests. SLL is an employee of Novartis Pharmaceutical Company; the statements presented in the paper do not necessarily represent the position of the company. The remaining authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>10</Day><Hour>8</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33688642</ArticleId><ArticleId IdType="pmc">PMC7941645</ArticleId><ArticleId IdType="doi">10.21203/rs.3.rs-266574/v1</ArticleId><ArticleId IdType="pii">rs.3.rs-266574</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hannah Ritchie EO-O, Beltekian D, Mathieu E, Hasell J. Bobbie Macdonald, Charlie Giattino, and Max Roser. Coronavirus Pandemic (COVID-19). 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7545176</ArticleId><ArticleId IdType="pubmed">33033256</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dowds J, O&#x2019;Brien K, Sheill G, Dyer AH, O&#x2019;Kelly B, et al. Persistent Poor Health Post-COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity. Ann Am Thorac Soc. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8456724</ArticleId><ArticleId IdType="pubmed">33413026</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemelli Against C-P-ACSG. Post-COVID-19 global health strategies: the need for an interdisciplinary approach. Aging Clin Exp Res. 2020;32(8):1613&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7287410</ArticleId><ArticleId IdType="pubmed">32529595</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A&#x2019;Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026.</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Allot A, Lu Z. LitCovid: an open database of COVID-19 literature. Nucleic Acids Res. 2021;49(D1):D1534&#x2013;D40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7778958</ArticleId><ArticleId IdType="pubmed">33166392</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.</Citation><ArticleIdList><ArticleId IdType="pubmed">25555855</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4320440</ArticleId><ArticleId IdType="pubmed">25554246</ArticleId></ArticleIdList></Reference><Reference><Citation>Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23963506</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2021;27(1):89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7510771</ArticleId><ArticleId IdType="pubmed">32979574</ArticleId></ArticleIdList></Reference><Reference><Citation>Goertz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324(6):603&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwan NA. Track. COVID-19 sickness, not just positive tests and deaths. Nature. 2020;584(7820):170.</Citation><ArticleIdList><ArticleId IdType="pubmed">32782377</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Neufeld KJ, Leoutsakos JS, Yan H, Lin S, Zabinski JS, Dinglas VD, et al. Fatigue Symptoms During the First Year Following ARDS. Chest. 2020;158(3):999&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478232</ArticleId><ArticleId IdType="pubmed">32304774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wostyn P. COVID-19 and chronic fatigue syndrome: Is the worst yet to come? Med Hypotheses. 2021;146:110469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836544</ArticleId><ArticleId IdType="pubmed">33401106</ArticleId></ArticleIdList></Reference><Reference><Citation>Vink M, Vink-Niese A. Could Cognitive Behavioural Therapy Be an Effective Treatment for Long COVID and Post COVID-19 Fatigue Syndrome? Lessons from the Qure Study for Q-Fever Fatigue Syndrome. Healthcare (Basel). 2020;8(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7764131</ArticleId><ArticleId IdType="pubmed">33322316</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamprecht B. [Is there a post-COVID syndrome?]. Pneumologe (Berl). 2020:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543035</ArticleId><ArticleId IdType="pubmed">33052198</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallanti S, Grassi E, Makris N, Gasic GP, Hollander E. Neurocovid-19: A clinical neuroscience-based approach to reduce SARS-CoV-2 related mental health sequelae. J Psychiatr Res. 2020;130:215&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7428715</ArticleId><ArticleId IdType="pubmed">32836010</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath A. Long-Haul COVID. Neurology. 2020;95(13):559&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">32788251</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Redefining an Illness. Mil Med. 2015;180(7):721&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">26126237</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A, Marshall T. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in the Era of the Human Microbiome: Persistent Pathogens Drive Chronic Symptoms by Interfering With Host Metabolism, Gene Expression, and Immunity. Front Pediatr. 2018;6:373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6288442</ArticleId><ArticleId IdType="pubmed">30564562</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingstone T, Taylor AK, O&#x2019;Donnell CA, Atherton H, Blane DN, Chew-Graham CA. Finding the &#x2018;right&#x2019; GP: a qualitative study of the experiences of people with long-COVID. BJGP Open. 2020;4(5).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7880173</ArticleId><ArticleId IdType="pubmed">33051223</ArticleId></ArticleIdList></Reference><Reference><Citation>Maury A, Lyoubi A, Peiffer-Smadja N, de Broucker T, Meppiel E. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians. Rev Neurol (Paris). 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832485</ArticleId><ArticleId IdType="pubmed">33446327</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldini T, Asioli GM, Romoli M, Carvalho Dias M, Schulte EC, Hauer L, et al. Cerebral venous thrombosis and SARS-CoV-2 infection: a systematic review and meta-analysis. Eur J Neurol. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014715</ArticleId><ArticleId IdType="pubmed">33426733</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7234781</ArticleId><ArticleId IdType="pubmed">32437679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacaro V, Chiabudini M, Buonanno C, De Bartolo P, Riemann D, Mancini F, et al. Insomnia in the Italian Population During Covid-19 Outbreak: A Snapshot on One Major Risk Factor for Depression and Anxiety. Front Psychiatry. 2020;11:579107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7769843</ArticleId><ArticleId IdType="pubmed">33384625</ArticleId></ArticleIdList></Reference><Reference><Citation>Mieczkowska K, Deutsch A, Borok J, Guzman AK, Fruchter R, Patel P, et al. Telogen effluvium: a sequela of COVID-19. Int J Dermatol. 2021;60(1):122&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7753411</ArticleId><ArticleId IdType="pubmed">33226117</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361108</ArticleId><ArticleId IdType="pubmed">32838236</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng CK, Chan JW, Kwan TL, To TS, Chan YH, Ng FY, et al. Six month radiological and physiological outcomes in severe acute respiratory syndrome (SARS) survivors. Thorax. 2004;59(10):889&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1746851</ArticleId><ArticleId IdType="pubmed">15454656</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Zhang Z, Shi Y, Jiang Y. Emerging. H7N9 influenza A (novel reassortant avian-origin) pneumonia: radiologic findings. Radiology. 2013;268(3):882&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23821754</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Tan C, Wu J, Chen M, Wang Z, Luo L, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020;21(1):163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323373</ArticleId><ArticleId IdType="pubmed">32600344</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60(5):401&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1758905</ArticleId><ArticleId IdType="pubmed">15860716</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouse BT, Sehrawat S. Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol. 2010;10(7):514&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3899649</ArticleId><ArticleId IdType="pubmed">20577268</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">32303591</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngai JC, Ko FW, Ng SS, To KW, Tong M, Hui DS. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology. 2010;15(3):543&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7192220</ArticleId><ArticleId IdType="pubmed">20337995</ArticleId></ArticleIdList></Reference><Reference><Citation>Suliman YA, Dobrota R, Huscher D, Nguyen-Kim TD, Maurer B, Jordan S, et al. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease. Arthritis Rheumatol. 2015;67(12):3256&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">26316389</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason L, Benton M, Torres-Harding S, Muldowney K. The impact of energy modulation on physical functioning and fatigue severity among patients with ME/CFS. Patient Educ Couns. 2009;77(2):237&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2767446</ArticleId><ArticleId IdType="pubmed">19356884</ArticleId></ArticleIdList></Reference><Reference><Citation>White PD, Goldsmith KA, Johnson AL, Potts L, Walwyn R, DeCesare JC, et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet. 2011;377(9768):823&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065633</ArticleId><ArticleId IdType="pubmed">21334061</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>